# A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe.

> **NCT07301866** · PHASE1,PHASE2 · RECRUITING · sponsor: **Ciusss de L'Est de l'Île de Montréal** · enrollment: 7 (estimated)

## Conditions studied

- Acute Leukemia, High Risk
- Myelodysplastic Syndromes, High Risk
- Hematologic Malignancy Requiring an Allogeneic Hematopoietic Stem Cell Transplant Lacking a Donor

## Interventions

- **BIOLOGICAL:** ECT-001-CB

## Key facts

- **NCT ID:** NCT07301866
- **Lead sponsor:** Ciusss de L'Est de l'Île de Montréal
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-06
- **Primary completion:** 2027-10
- **Final completion:** 2028-03
- **Target enrollment:** 7 (ESTIMATED)
- **Last updated:** 2025-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07301866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07301866, "A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07301866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*